Latest News on GH

Financial News Based On Company


Advertisement
Advertisement

Form 4 Guardant Health Inc: Medina Manuel Hidalgo (Director) For: 17 November

https://ca.investing.com/news/stock-market-news/form-4-guardant-health-inc-medina-manuel-hidalgo-director-for-17-november-93CH-4968546
This article reports on a Form 4 filing for Guardant Health Inc, detailing an insider transaction by Director Medina Manuel Hidalgo. The filing pertains to activity on November 17. The article provides minimal details beyond the announcement of the Form 4.

Guardant Health director Tariq Musa sells $17,348 in company stock By Investing.com

https://uk.investing.com/news/stock-market-news/guardant-health-director-tariq-musa-sells-17348-in-company-stock-93CH-4989556
Guardant Health director Tariq Musa sold 116 shares of the company's common stock for $17,348 following a 50% surge in stock value. This sale occurred after an acquisition of 250 shares through restricted stock unit vesting. InvestingPro analysis suggests the stock is currently overvalued.

Form 4 Guardant Health Inc: Musa Tariq (Director) For: 15 November

https://ca.investing.com/news/stock-market-news/form-4-guardant-health-inc-musa-tariq-director-for-15-november-93CH-4965829
This article reports on a Form 4 filing for Guardant Health Inc., indicating that director Musa Tariq was involved in a transaction on November 15. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The article is a brief notification of this filing.

Guardant Health director Tariq Musa sells $17,348 in company stock By Investing.com

https://ca.investing.com/news/stock-market-news/guardant-health-director-tariq-musa-sells-17348-in-company-stock-93CH-4965818
Guardant Health Director Tariq Musa sold 116 shares of company stock worth $17,348 on November 16, 2026, after the stock surged 50% in six months and was deemed overvalued by InvestingPro. This sale followed his acquisition of 250 shares through restricted stock unit vesting. Despite positive Q3 revenue exceeding forecasts, investor concerns about cash burn led to a stock sell-off, though BTIG reiterated a Buy rating.

Guardant Health director Alex Azar II sells $10,319 in shares By Investing.com

https://in.investing.com/news/stock-market-news/guardant-health-director-alex-azar-ii-sells-10319-in-shares-93CH-5711071
Alex M. Azar II, a director at Guardant Health, Inc. (NASDAQ:GH), sold 69 shares of common stock for approximately $10,319 on November 16, 2026. Following this transaction, Mr. Azar II directly holds 962 shares. Despite the company's stock being up 51% over the past six months, InvestingPro analysis suggests it is overvalued and the company is not expected to be profitable this year.
Advertisement

Form 4 Guardant Health Inc: Alex M. Azar II (Director) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-guardant-health-inc-alex-m-azar-ii-director-for-16-november-93CH-5711085
This article reports on a Form 4 filing for Guardant Health Inc., indicating an insider transaction by Director Alex M. Azar II on November 16. The brief notice highlights the company (GH) and the specific date of the director's transaction.

Form 144 Guardant Health For: 16 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-guardant-health-for-16-november-93CH-4962259
This article announces the filing of Form 144 for Guardant Health (GH) on November 16. It includes a brief mention of GH's stock performance (-5.06%) within market data. The content is primarily a placeholder for the Form 144 announcement.

Reflecting on testing & diagnostics services stocks’ Q3 earnings: Guardant Health

https://www.tradingview.com/news/stockstory:ab8e6c3ea094b:0-reflecting-on-testing-diagnostics-services-stocks-q3-earnings-guardant-health/
This article reviews the Q3 earnings of testing & diagnostics services stocks, focusing on Guardant Health (GH) which reported strong revenue growth and exceeded analyst expectations. It also highlights the performance of other companies in the sector, including NeoGenomics (NEO), Quest Diagnostics (DGX), Labcorp (LH), and RadNet (RDNT), detailing their revenue, growth, and market reactions. The sector as a whole experienced solid Q3 results with revenues beating consensus estimates.

What Is Guardant Health (GH) Signaling With Its $500 Million Convertible Note Offering?

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/what-is-guardant-health-gh-signaling-with-its-500-million-co
Guardant Health (NasdaqGS: GH) recently completed a US$500 million convertible note offering to enhance its capital needs, supporting research, potential deals, and expansion of its cancer diagnostic platform. This financing, while providing crucial funding for growth and initiatives like Shield screening and Guardant360, introduces dilution risk and increased leverage for investors. The company aims to move towards cash generation, but the success of this strategy will depend on stabilizing net debt and the debt-to-equity mix over the next 12-24 months.

Fund Update: 313,709 GUARDANT HEALTH (GH) shares added to MANNING & NAPIER ADVISORS LLC portfolio

https://www.quiverquant.com/news/Fund+Update%3A+313%2C709+GUARDANT+HEALTH+%28GH%29+shares+added+to+MANNING+%26+NAPIER+ADVISORS+LLC+portfolio
MANNING & NAPIER ADVISORS LLC has increased its holdings in Guardant Health (GH) by 313,709 shares, as detailed in a recent SEC 13F filing for the 09-30-2026 report period. The article also provides a comprehensive overview of recent hedge fund activity, insider trading, congressional stock trades, and analyst price targets for GH. While many institutional investors have added GH shares, there have been significantly more insider sales than purchases in the past six months.
Advertisement

What Could Guardant Health (GH) New Cancer Test Tools Mean For Oncologists?

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/what-could-guardant-health-gh-new-cancer-test-tools-mean-for
Guardant Health (GH) has launched five new epigenomic applications for its Guardant360 Liquid test, specifically targeting breast and lung cancers. These tools, powered by the InfinityAI platform, aim to assist oncologists in selecting therapies for patients whose tumors lack clear genomic biomarkers. This expansion is expected to broaden the clinical utility and addressable market for Guardant360 Liquid testing, reinforcing the company's "multi omics data and InfinityAI" growth narrative.

Form 4 Guardant Health Inc: Robert Parks (Chief Accounting Officer) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-guardant-health-inc-robert-parks-chief-accounting-officer-for-9-november-93CH-5701826
This article reports a Form 4 filing for Guardant Health Inc., indicating a transaction by Robert Parks, the Chief Accounting Officer, on November 9th. Form 4 documents are used to declare changes in beneficial ownership of securities by a company's insiders. The article does not provide further details on the nature of the transaction.

Guardant Health plans $500M convertible note offering and related 2027 note repurchases

https://www.tradingview.com/news/seekingalpha:71c133008094b:0-guardant-health-plans-500m-convertible-note-offering-and-related-2027-note-repurchases/
Guardant Health announced its intention to offer $500M in convertible senior notes due 2032 through a private offering, with an option for initial purchasers to buy an additional $50M. The company plans to use a portion of the net proceeds to repurchase some of its 0% convertible senior notes due 2027 and to fund capped call transactions. These financial maneuvers aim to manage the company's debt structure.

Guardant Health prices $500M convertible notes offering

https://www.tradingview.com/news/seekingalpha:14743ec66094b:0-guardant-health-prices-500m-convertible-notes-offering/
Guardant Health (GH) has priced a private offering of $500 million in 0% convertible senior notes due 2032, with an option for initial purchasers to acquire an additional $50 million. The initial conversion price is set at $208.95 per share, representing a 35% premium over its recent closing price. The company intends to use the net proceeds, estimated at $489.3 million, to repurchase a significant portion of its outstanding 0% convertible notes due 2027 and to fund capped call transactions.

Guardant Health Prices $500 Million Convertible Senior Notes Offering

https://finance.yahoo.com/markets/stocks/articles/guardant-health-prices-500-million-060900432.html
Guardant Health, Inc. has priced a private offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032. The notes will be senior, unsecured obligations, with an initial conversion price of approximately $208.95 per share, representing a 35.0% premium over Guardant Health's common stock. The company expects to use the net proceeds to repurchase a portion of its 2027 convertible senior notes and to fund capped call transactions.
Advertisement

Could You Have Seen The Run In Guardant Health Stock Coming?

https://www.trefis.com/stock/gh/articles/624232/could-you-have-seen-the-run-in-guardant-health-stock-coming/2026-11-11
Guardant Health (GH) stock has seen a significant run, gaining 60.6% in the last year and 131.8% in the six months prior to November 10, 2026, primarily driven by the success of its Shield colorectal cancer screening test. Early indicators of this growth included FDA approval and Medicare coverage for Shield by June 2025, followed by accelerating revenue growth and shrinking operating losses for the company by October 2025. While Shield's adoption continues to build and is expected to reach cash flow breakeven by the end of 2028, Guardant's overall operating loss as a percentage of revenue has remained relatively stable, making it a key metric to watch.

Guardant Health plans $500M convertible notes offering due 2032

https://www.streetinsider.com/Corporate+News/Guardant+Health+plans+%24500M+convertible+notes+offering+due+2032/27328034.html
Guardant Health, Inc. announced a proposed private offering of $500.0 million in convertible senior notes due 2032 to qualified institutional buyers. The company also intends to grant initial purchasers an option to buy an additional $50.0 million in notes. Proceeds from the offering will be used to repurchase existing 0% convertible senior notes due 2027, fund capped call transactions to reduce dilution, and for general corporate purposes.

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032

https://finance.yahoo.com/markets/stocks/articles/guardant-health-announces-proposed-500-211700329.html
Guardant Health, Inc. announced a proposed private offering of $500.0 million in convertible senior notes due 2032, with an option for initial purchasers to acquire an additional $50.0 million. The company plans to use a portion of the net proceeds to repurchase existing 0% convertible senior notes due 2027 and to fund capped call transactions designed to reduce potential stock dilution. The offering is subject to market conditions, and the notes will be senior, unsecured obligations maturing in May 2032.

Guardant Health adds five epigenomic cancer-testing tools

https://mugglehead.com/guardant-health-epigenomic-applications-cancer-treatment-selection/
Guardant Health has expanded its Guardant360 Liquid blood test with five new epigenomic applications designed to improve breast and lung cancer treatment selection. These additions use the company's InfinityAI platform to combine genomic and epigenomic signals, aiming to inform therapy choices when conventional mutation markers are insufficient. The company reported $231.3 million in third-quarter revenue, with oncology test volume up 58 percent year-over-year.

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid

https://www.quantisnow.com/insight/guardant-health-introduces-new-epigenomic-applications-providing-deeper-insights-for-6785306
Guardant Health announced new epigenomic applications for its Guardant360 Liquid blood test, powered by its InfinityAI platform. These applications aim to provide deeper insights for treatment selection in breast and lung cancer by combining genomic and epigenomic data, potentially identifying ALK fusions and MTAP deletions that genomic testing might miss. While the company highlights expanded capabilities, the release does not include financial impact, commercial terms, or availability dates for these new features.
Advertisement

Guardant360® Tissue Receives MOHW LDTS approval in Taiwan

https://www.manilatimes.net/2026/11/11/tmt-newswire/pr-newswire/guardant360-tissue-receives-mohw-ldts-approval-in-taiwan/2467208
Guardant Health's Guardant360® Tissue test has received Laboratory Developed Tests and Services (LDTS) approval from Taiwan's Ministry of Health and Welfare (MOHW). This approval provides a pathway for reimbursement coverage and makes the test progressively available in major hospitals across Taiwan. The Guardant360 Tissue test offers comprehensive genomic and epigenomic insights for advanced solid tumors, requiring minimal tissue samples, and is powered by InfinityAI for enhanced clinical decision-making.

Learn Why The Bull Case For Guardant Health Stock Could Change Following Revenue Guidance Raise

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/learn-why-the-bull-case-for-guardant-health-stock-could-chan
Guardant Health (NasdaqGS:GH) reported Q3 2026 sales of US$360.98 million and raised its full-year 2026 revenue guidance to US$1.36 to US$1.37 billion due to strong demand for its cancer screening and oncology tests. While this revenue growth supports the bullish narrative, the company continues to report significant net losses, keeping focus on cash burn and the path to profitability. Analyst models project rapid revenue expansion and a sharp swing to profitability over the next few years, but also factor in dilution and a rich valuation.

What Sent Guardant Health Stock Higher?

https://www.trefis.com/stock/gh/articles/624112/what-sent-guardant-health-stock-higher/2026-11-10
Guardant Health (GH) stock rose 5.2% on November 9, 2026, outperforming the S&P 500, despite no direct company announcement. The rise followed the company's third-quarter report on November 5, where it announced a 36% revenue growth, a 180% increase in Shield revenue, and raised its full-year 2026 revenue outlook. The company also adjusted its free cash flow burn outlook due to a temporary delay in CMS claims processing for a new test.

Guardant Health will give two conference talks, with live and archived webcasts.

https://www.stocktitan.net/news/GH/guardant-health-to-participate-in-upcoming-investor-7ah4bjnze3cd.html
Guardant Health (Nasdaq: GH) announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference on November 18 and the Piper Sandler 38th Annual Healthcare Conference on December 1. The company will host fireside chats at both events, with live and archived webcasts available on its investor relations website. Guardant Health is a precision oncology company focused on improving cancer care through advanced blood and tissue tests, real-world data, and AI analytics.

Guardant Health (GH) Stock May Be 29% Undervalued Despite Higher Cash Burn

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-stock-may-be-29-undervalued-despite-highe
Guardant Health (GH) stock may be undervalued by 29% based on a Discounted Cash Flow (DCF) model, despite the company currently experiencing a cash burn. Analysts forecast a shift from cash drain to cash generation in the coming years, which supports the higher intrinsic value compared to its current share price of $150.87. However, the market has not fully reflected these longer-term projections due to a recent forecast of higher full-year cash burn.
Advertisement

People in the News at Guardant Health, 10x Genomics, Qiagen, Mirvie, Lilac Biosciences

https://www.genomeweb.com/news/gnw-guardant-10x-qiagen-mirvie-lilacbio-20261109/
This article reports on new hires at several prominent biotechnology and life sciences companies. Guardant Health, 10x Genomics, Qiagen, Mirvie, and Lilac Biosciences have all brought on new personnel, indicating potential growth or strategic shifts within these organizations.

Guardant Health, Inc. (GH) Seasonal returns chart

https://au.finance.yahoo.com/quote/GH/seasonality/
This article from Yahoo Finance focuses on the seasonal returns chart for Guardant Health, Inc. (GH). It provides current stock performance data, including its price and recent changes, and offers an average monthly price return analysis from 2018-2026. The page also mentions the company's Q3 2026 earnings call for further insights.

Guardant Health Stocks Fall 9.49% as Cash Burn Outlook Rises Despite 36% Growth

https://www.tradingview.com/news/gurufocus:bc053a02f094b:0-guardant-health-stocks-fall-9-49-as-cash-burn-outlook-rises-despite-36-growth/
Guardant Health (GH) shares dropped 9.49% after the company increased its full-year free cash flow burn outlook, despite reporting a 36% rise in third-quarter revenue to $361 million. While screening revenue significantly jumped and overall revenue guidance for 2026 was lifted, an increase in non-GAAP operating expenses and a widening GAAP net loss concerned investors. The company's GF Score indicates weak profitability and GF Value, with shares trading at approximately twice its GF Value.

TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent

https://www.biospace.com/press-releases/twinstrand-biosciences-announces-uspto-confirmation-of-patentability-of-core-duplex-sequencing-patent
TwinStrand Biosciences announced that the USPTO has confirmed the patentability of all 23 claims of its '631 patent, a foundational patent for its Duplex Sequencing technology. This decision, which is unappealable, follows a previous PTAB ruling upholding all 30 claims of the related '127 patent, further solidifying TwinStrand's intellectual property in its patent infringement litigation against Guardant Health. The confirmed validity of both patents supports the August 2026 final judgment awarding TwinStrand over $245.2 million in damages and ongoing royalties from Guardant Health.

Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36% as Shield ...

https://sg.finance.yahoo.com/news/guardant-health-inc-gh-q3-052630647.html
Guardant Health Inc. reported a 36% year-over-year revenue increase to $361 million in Q3 2026, driven by strong growth in oncology and a significant surge in Shield screening revenue. The company raised its full-year 2026 revenue guidance to $1.36-$1.37 billion and expects to achieve company-wide free cash flow breakeven by the end of 2027. Despite increased operating expenses and a temporary delay in CMS claims processing, Guardant Health's FDA approval for Guardant360 CDX and the scaling of its Shield screening platform position it for continued growth.
Advertisement

Guardant Health Q3 Results: Adjusted loss narrows 25% YoY to $(0.29)

https://scanx.trade/stock-market-news/companies/guardant-health-q3-results-adjusted-loss-narrows-25-yoy-0-29/55459437
Guardant Health reported a 36% year-over-year revenue increase to $361 million in Q3, leading to raised full-year 2026 revenue guidance of $1.36-$1.37 billion. The company's adjusted loss per share narrowed by 25.64% to $(0.29), beating analyst estimates. This performance was driven by strong growth in both oncology and the SHIELD screening segment, coupled with improved cost efficiency.

Guardant Health Stock Slides 12% After Cash Burn Forecast Widens Despite Revenue Beat

https://finance.biggo.com/news/58e3fd75-1657-4002-a99a-a22b5f390c7d
Guardant Health's stock fell 12% after the company beat third-quarter revenue and adjusted loss estimates but increased its full-year cash burn forecast due to a CMS billing system delay. Despite strong growth in screening revenue and overall revenue, the revised free cash flow burn guidance overshadowed the positive operational results and prompted investor concern regarding the company's 2027 breakeven target.

Guardant Health falls 12% as cash burn guidance disappoints

https://www.investing.com/news/earnings/guardant-health-falls-12-as-cash-burn-guidance-disappoints-5006025
Guardant Health Inc. (NASDAQ:GH) saw its shares drop 12% in after-hours trading despite reporting third-quarter results that surpassed analyst expectations for both adjusted earnings per share and revenue. The decline was primarily driven by the company's decision to raise its full-year free cash flow burn guidance, overshadowing improved revenue projections for 2026. Despite this, the precision oncology company reported strong growth across its oncology, screening, and biopharma & data segments, and expanded commercial coverage for its Shield product.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

https://sg.finance.yahoo.com/news/guardant-health-gh-reports-q3-000008709.html
Guardant Health (GH) reported a Q3 loss of $0.29 per share, matching the Zacks Consensus Estimate, and surpassed revenue estimates with $360.98 million. The company has topped consensus revenue estimates four times in the last four quarters, with its shares gaining 65.1% year-to-date. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.

Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-5-guardant-healths-nasdaqgh-q3-2026-sales-beat-estimates-but-stock-drops-102
Guardant Health (NASDAQ: GH) surpassed Wall Street's revenue and EPS expectations in Q3 2026, with revenue increasing 36.1% year-on-year to $361 million and a non-GAAP loss of $0.29 per share. Despite these positive results and an increased full-year revenue guidance, the company's stock declined by 10.2% immediately after the announcement. This suggests that while the financial performance was strong, the market may have anticipated even more significant upside.
Advertisement

Guardant Health Q3 Revenue Climbs 36 Percent as Firm Raises Full-Year Guidance

https://www.genomeweb.com/diagnostics/molecular/liquid-biopsy/ctdna/gnw-guardant-health-q3-financial-results-20261105/
Guardant Health reported a 36 percent increase in its third-quarter revenue, leading the firm to raise its full-year guidance. The company's financial performance signals strong growth within the precision medicine and cancer diagnostics sector.

Guardant Health (GH) Added Kevin Sayer To Its Board

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-added-kevin-sayer-to-its-board
Guardant Health (NasdaqGS:GH) has appointed digital health veteran Kevin Sayer to its board of directors, following its recognition with the Prix Galien USA Award for its Shield blood test and inclusion in Business Insider’s 2024 list of America’s Most Innovative Businesses. This appointment and the recent accolades are expected to influence investor perception of Guardant Health's role in cancer screening, reinforcing the company's focus on data-driven diagnostics. The strategic move aims to strengthen the company's position in cancer screening and diagnostics, though challenges like managing patent royalties and cash burn remain.

Guardant Health (GH) Could Be 17% Undervalued As Board Appointment Tests Valuation

https://sg.finance.yahoo.com/news/guardant-health-gh-could-17-051903253.html
Guardant Health (GH) has appointed Kevin Sayer, former Dexcom CEO, to its board, prompting new questions about its stock valuation. While the company has seen short-term price pullbacks, its year-to-date and one-year returns remain strong, supported by recent awards and revenue growth. Despite screening as undervalued on fair value estimates with a target of $202.24, Guardant Health's P/S ratio of 19.1x is significantly higher than industry averages, suggesting it may appear expensive on sales.

Guardant Health earnings: what to look for from GH

https://www.tradingview.com/news/stockstory:b90426162094b:0-guardant-health-earnings-what-to-look-for-from-gh/
Guardant Health (GH) is set to report earnings, with analysts expecting a 32.2% year-on-year revenue growth, a slowdown from the previous year. The company has a history of exceeding expectations, and its peers like NeoGenomics and Labcorp have already reported positive Q3 results. Despite positive sentiment in the testing & diagnostics services segment, Guardant Health's stock is down 6.6% over the last month, trading below its average analyst price target.

Form 8K Guardant Health Inc For: 3 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-guardant-health-inc-for-3-november-93CH-5675057
This article from Investing.com announces the filing of a Form 8K by Guardant Health Inc on November 3, 2026. The 8K filing is a report that U.S. public companies must file with the Securities and Exchange Commission (SEC) to announce significant events that shareholders should know about. The article itself serves as a brief notification rather than an in-depth analysis of the filing's contents.
Advertisement

Guardant Health (GH) Heads To ESMO, Is The Premium Already Priced In?

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-heads-to-esmo-is-the-premium-already-pric
Guardant Health (GH) is presenting at the 2026 European Society for Medical Oncology Congress, which prompts a re-evaluation of its stock. Despite recent short-term dips, the company has seen strong year-to-date and 1-year returns, driven by accelerating adoption of its Shield colorectal cancer screening test. While some analysts view Guardant Health as undervalued, its high Price-to-Sales ratio suggests significant future expectations are already factored into the current share price.

Form 8K Guardant Health Inc For: 3 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-guardant-health-inc-for-3-november-93CH-2778228
This article announces that Guardant Health Inc. filed a Form 8K on November 3, 2026. The filing is available via Investing.com and notes a slight increase in Guardant Health's stock price. The content is brief and primarily serves as a notification of the SEC filing.

Form 8K Guardant Health Inc For: 3 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-guardant-health-inc-for-3-november-93CH-4952613
This article reports that Guardant Health Inc. filed a Form 8K on November 3, 2026. The filing is noted by Investing.com, indicating a significant event that shareholders and investors may need to review. The article itself is brief, primarily serving as an announcement of the filing.

Guardant Health grants performance-based stock awards to co-CEOs Helmy Eltoukhy and AmirAli Talasaz

https://www.tradingview.com/news/tradingview:e44a7076f70bb:0-guardant-health-grants-performance-based-stock-awards-to-co-ceos-helmy-eltoukhy-and-amirali-talasaz/
Guardant Health (GH) has granted performance-based restricted stock units to its co-CEOs, Helmy Eltoukhy and AmirAli Talasaz. These awards are tied to the company's relative shareholder returns over three- and five-year periods and are designed to align executive compensation with long-term value creation. Each CEO received 465,413 PSUs at target, with a maximum payout of 250% subject to performance and continued service.

Guardant Health (GH) Stock Looks Cheap With Screening Growth In View

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-stock-looks-cheap-with-screening-growth-i
Guardant Health's stock has risen significantly, prompting an assessment of whether its cash flows justify its current valuation of US$178.80. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued, with projections of positive free cash flow by the early 2030s, partly driven by expanded colorectal cancer screening access. However, community narratives offer both bull and bear cases, with some seeing further upside from screening adoption and others highlighting risks like a patent judgment and royalties.
Advertisement

Understanding Momentum Shifts in (GH)

https://news.stocktradersdaily.com/news_release/149/Understanding_Momentum_Shifts_in_GH_110126011201_1793556721.html
This article analyzes Guardant Health Inc. (NYSE: GH), highlighting a strong sentiment across all horizons and an exceptional 57.2:1 risk-reward setup targeting a 16.4% gain versus 0.3% risk. It outlines three distinct AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with a multi-timeframe signal analysis.

Should Expanded Screening Coverage Require Action From Guardant Health Stock Investors?

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/should-expanded-screening-coverage-require-action-from-guard
Guardant Health (NasdaqGS:GH) is seeing increased investor interest due to anticipated Q3 2026 results and a new Pennsylvania law that expands colorectal cancer screening coverage for approximately 2 million residents. This legislation, effective December 21, 2026, is expected to boost demand for Guardant Health's Shield blood test by removing cost-sharing for many insured adults. Investors are now closely watching the impact of this policy momentum on test uptake, cost reduction targets, and the company's long-term revenue and earnings projections.

Guardant Health, Inc. (GH) Seasonal returns chart

https://uk.finance.yahoo.com/quote/GH/seasonality/
This article provides a seasonal returns chart for Guardant Health, Inc. (GH), showcasing average monthly price returns from 2018 to 2026. It also includes current stock information, recent price changes, and details about the upcoming Q3 2026 earnings call. The content is hosted on Yahoo Finance.

Guardant Health, Inc. (GH) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/GH/seasonality/
This article provides a seasonal returns chart for Guardant Health, Inc. (GH) on Yahoo Finance. It displays the average monthly price return for GH from 2018 to 2026 and includes current stock data and an announcement for the Q3 2026 earnings call.

Guardant Health options signal 14% stock move on earnings By Investing.com

https://ca.investing.com/news/stock-market-news/guardant-health-options-signal-14-stock-move-on-earnings-93CH-4914738
Guardant Health Inc. shares could see a 14% movement following its upcoming earnings report on November 5, according to options data. Historically, the stock has often exceeded its implied move after earnings announcements, notably jumping 36.9% on October 29, 2025, against an 8.6% implied move. The most recent report on July 30 showed a 7.5% price change versus a 10.6% implied move.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement